ACTIVE

DERMAX

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result517,6 k €-80,3 %over 1 year
Revenue1,6 M €
Equity5,3 M €+10,8 %over 1 year

Identity

Source · BCE/KBO

DERMAX is a Public limited company incorporated in 2016. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Liège.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0667.730.677
Incorporation
15/12/2016
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège · WallonieSee on map
Contributed capital
3 250 022,00 €
Latest accounts
31/12/2025
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

Financials

Source · NBB, 9 filings

Trend over 9 financial years

20252024202320222021
Income statement
Revenue1,6 M €––––
EBITDA1,2 M €3,3 M €374,1 k €1,2 M €-3,5 k €
Operating result937,9 k €2,9 M €35,1 k €166,9 k €-105,8 k €
Net result517,6 k €2,6 M €116,7 k €276,8 k €-194,9 k €
Balance sheet
Equity5,3 M €4,8 M €2,2 M €3 M €2,8 M €
Total assets5,7 M €6,6 M €5,7 M €7,1 M €6,7 M €
Cash168,2 k €257,5 k €304,6 k €1,7 M €2,7 M €
Debts414,3 k €1,6 M €3,2 M €3,7 M €3,4 M €

Valuation

Indicative valuation

As an indication, this company is worth

between 10 M€ and 25 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 2 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Jacobsen Management0736.534.955Represented by Thomas Jacobsen
Director20/04/2020 → 09/06/2026
SVR Management0552.806.859Represented by Stijn Van Rompay
Managing director20/04/2020 → 09/06/2026Directorlisted until the 2019 accountsended

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
GRNR Invest0817.694.459Represented by Thomas Jacobsen
Director05/12/2016 → 2020 accounts
SVR INVEST0479.774.371Represented by Stijn Van Rompay
Director05/12/2016 → 20/04/2020Managing director05/12/2016 → 2017 accounts

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège
CompanyCBE no.
Abscint● Active
0749.828.410
Aeroforge● Active
1044.274.185
AMPACIMON● Active
0827.990.317
Amyl Therapeutics● Active
0758.775.372
BECARV● Bankrupt
0840.777.885
BE.SPINE● Active
1013.110.857
CATALYA● Active
0727.648.171
CEFALY Technology● Active
0870.578.661
DIANOSIC● Active
1034.558.646
DW Cefaly Holding● Active
0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active
1023.778.481
EXO Biologics● Active
0732.982.379
ExoXpert● Active
1003.807.666
EYED PHARMA● Active
0508.599.605
Hirundo Biosciences● Active
0681.855.065
HolyFox Invest● Active
1010.693.181
Hyloris● Active
0669.738.676
Hyloris Developments● Active
0542.737.368
Hyloris Pharmaceuticals● Active
0674.494.151
Hyloris Therapeutics● Active
1025.029.385

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date07/07/202604/07/202515/11/202411/07/202312/07/202206/07/2021
General meeting30/06/202610/06/202514/11/202413/06/202314/06/202208/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 9 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/06/202607/07/2026FrenchPDF
Abridged model31/12/202410/06/202504/07/2025FrenchPDF
Abridged model31/12/202314/11/202415/11/2024FrenchPDF
Abridged model31/12/202213/06/202311/07/2023FrenchPDF
Abridged model31/12/202114/06/202212/07/2022FrenchPDF
Abridged model31/12/202008/06/202106/07/2021FrenchPDF
Abridged model31/12/201908/06/202030/07/2020FrenchPDF
Abridged model31/12/201812/08/201926/08/2019FrenchPDF
Micro model31/12/201710/08/201831/08/2018FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 10 M€ and 25 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 2 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Jacobsen Management0736.534.955Represented by Thomas Jacobsen
Director20/04/2020 → 09/06/2026
SVR Management0552.806.859Represented by Stijn Van Rompay
Managing director20/04/2020 → 09/06/2026Directorlisted until the 2019 accountsended

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
GRNR Invest0817.694.459Represented by Thomas Jacobsen
Director05/12/2016 → 2020 accounts
SVR INVEST0479.774.371Represented by Stijn Van Rompay
Director05/12/2016 → 20/04/2020Managing director05/12/2016 → 2017 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates26/09/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates05/03/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates19/05/2023
    DEMISSIONS, NOMINATIONS
    PDF
  • Registered office20/10/2022
    SIEGE SOCIAL - DIVERS
    PDF
  • Registered office07/09/2022
    SIEGE SOCIAL
    PDF
  • Mandates30/07/2021
    DEMISSIONS, NOMINATIONS
    PDF
  • Capital / shares28/10/2020
    CAPITAL, ACTIONS
    PDF
  • Capital / shares24/09/2020
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings9 filings
Mandates
SVR Management
Jacobsen Management
SVR INVEST
GRNR Invest
20162017201820192020202120222023202420252026
DERMAX
Boulevard de Patience et Beaujonc 3 bte 1, 4000 Liège
Managing director
Director
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Boulevard de Patience et Beaujonc 3 bte 1, 4000 LiègeCurrent
accounts 2022 → 2025
Accounts 2025 · 2026-00271045
Boulevard Gustave-Kleyer 17, 4000 Liège
accounts 2021
Accounts 2021 · 2022-20200974

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
DERMAXCurrent
accounts 2017 → 2025
Accounts 2025 · 2026-00271045

Events

  1. 2025
    Annual accounts 2025517,6 k €↓
  2. 2024
    Annual accounts 20242,6 M €↑
  3. 2023
    Annual accounts 2023116,7 k €↓
  4. 2022
    Annual accounts 2022276,8 k €↑
  5. 2021
    Annual accounts 2021-194,9 k €↑
  6. 2020
    Annual accounts 2020-283,7 k €↑
  7. 2019
    Annual accounts 2019-742,8 k €↓
  8. 2018
    Annual accounts 2018-202,4 k €↓
  9. 2017
    Annual accounts 2017-16,5 k €
  10. 15/12/2016
    IncorporationPublic limited company